2026-10-19T01:56:15Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/146232026-10-18T21:14:24Zopenairedrivercom_ebyu_10000col_ebyu_10001

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial CancerYıldırım, Malik EjderKarakuş, SavasKurtulgan, Hande KüçükKılıçgün, HasanErşan, SerpilBakır, SevtapEndometrial cancerGradesPAI-1 4G/5G polymorphismPAI-1 levelsAdultAgedEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticGenetic Association StudiesGenetic Predisposition to DiseaseGenotypeHumansMiddle AgedNeoplasm GradingPlasminogen Activator Inhibitor 1Polymorphism, Single NucleotidePromoter Regions, Geneticgenomic DNASERPINE1 protein, humanalleleArticlebody masscancer gradingcancer growthcancer patientcarcinogenesiscontrolled studyDNA polymorphismendometrium carcinomaPlasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (Serpine 1), and it inhibits both tissue plasminogen activator and urokinase plasminogen activator which are important in fibrinolysis. We aimed to find whether there is a possible association between PAI-1 level, PAI-1 4G/5G polymorphism, and endometrial cancer. PAI-1 levels in peripheral blood were determined in 82 patients with endometrial carcinoma and 76 female healthy controls using an enzyme-linked immunoassay (ELISA). Then, the genomic DNA was extracted and screened by reverse hybridization procedure (Strip assay) to detect PAI 1 4G/5G polymorphism. The levels of PAI-1 in the patients were higher statistically in comparison to controls (P < 0.001). The distribution of PAI-1 4G/5G polymorphism was quite different between patients and controls (P = 0.008), and 4G allelic frequency was significantly higher in the patients of endometrial cancer than in controls (P = 0.026). We found significant difference between Grade 1 and Grade 2+3 patients in terms of the PAI-1 levels (P = 0.047). There was no association between PAI-1 4G/5G polymorphism and the grades of endometrial cancer (P = 0.993). Our data suggest that the level of PAI-1 and PAI-1 4G/5G gene polymorphism are effective in the formation of endometrial cancer. PAI-1 levels are also associated with the grades of endometrial cancer. © 2017, Springer Science+Business Media New York.Springer New York LLC2017Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/14623https://doi.org/10.1007/s10528-017-9796-70006-2928enBiochemical Geneticsinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/14623